A pilot randomized controlled trial of a tailored smoking cessation program for people living with HIV in the Washington, D.C. metropolitan area

Table 2 Primary and secondary outcomes of participants enrolled in a randomized controlled trial of a tailored smoking cessation intervention for people with HIV in the Washington, D.C. metro area, from baseline to 30-day follow-up, by treatment group (n = 25)

	Median (IQR)	Median (IQR)	Median (IQR) Change	p-value^c	Median (IQR)	Median (IQR)	Median (IQR) Change	p-value^c
Cigarettes per day^a	9.0 (1.0, 15.0)	0.5 (0.0, 3.0)	− 0.5 (-15.0,0.0)	0.0586	15.0 (6.0, 20.0)	3.0 (0.0, 10.0)	− 10.0 (− 19.0, − 3.0)	0.0020	0.1652
Cigarettes per day among those not quit^b	3.0 (1.0, 10.0)	3.0 (1.0, 5.0)	0.0 (0.0,1.0)	0.8125	20.0 (9.0, 25.0)	4.0 (2.0, 11.0)	− 13.5 (− 19.5, − 2.5)	0.0156	0.0358
Carbon Monoxide (ppm)	14.0 (10.0, 24.0)	7.0 (4.0,14.0)	− 5.0 (− 9.0,4.0)	0.0005	19.5 (11.0, 23.5)	12.5 (11.5, 20.0)	− 4.5 (− 9.0, 1.0)	0.0488	0.4172
Self Efficacy (Scale: 0-4)	1.8 (1.0, 2.5)	2.5 (1.5, 3.0)	0.3 (0.0, 1.0)	0.0488	1.0 (0.5, 2.5)	2.0 (2.0, 4.0)	1.0 (− 0.5, 2.0)	0.0117	0.4989

^aCigarettes per day in the total sample. All those who quit have a CPD of zero. (n = 25)
^bCigarettes per day in those who did not quit. All those who quit excluded. (n = 17)
^cSignificant differences tested from baseline to follow-up
^dSignificant differences tested between study groups

ISSN: 1756-0500